Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 710

1.

The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer.

Aljohani AI, Toss MS, Kurozumi S, Joseph C, Aleskandarany MA, Miligy IM, Ansari RE, Mongan NP, Ellis IO, Green AR, Rakha EA.

Breast Cancer Res Treat. 2019 Oct 10. doi: 10.1007/s10549-019-05459-7. [Epub ahead of print]

PMID:
31599393
2.

Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer.

Joseph C, Al-Izzi S, Alsaleem M, Kurozumi S, Toss MS, Arshad M, Goh FQ, Alshankyty IM, Aleskandarany MA, Ali S, Ellis IO, Mongan NP, Green AR, Rakha EA.

Br J Cancer. 2019 Oct;121(9):776-785. doi: 10.1038/s41416-019-0589-0. Epub 2019 Sep 27.

PMID:
31558802
3.

Activated zinc transporter ZIP7 as an indicator of anti-hormone resistance in breast cancer.

Ziliotto S, Gee JMW, Ellis IO, Green AR, Finlay P, Gobbato A, Taylor KM.

Metallomics. 2019 Sep 1;11(9):1579-1592. doi: 10.1039/c9mt00136k. Epub 2019 Sep 4.

4.

CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.

Alfarsi LH, Ansari RE, Craze ML, Toss MS, Masisi B, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res Treat. 2019 Dec;178(3):535-544. doi: 10.1007/s10549-019-05420-8. Epub 2019 Aug 30.

PMID:
31471836
5.

Machine learning-based prediction of breast cancer growth rate in vivo.

Bhattarai S, Klimov S, Aleskandarany MA, Burrell H, Wormall A, Green AR, Rida P, Ellis IO, Osan RM, Rakha EA, Aneja R.

Br J Cancer. 2019 Sep;121(6):497-504. doi: 10.1038/s41416-019-0539-x. Epub 2019 Aug 9.

PMID:
31395950
6.

A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk.

Klimov S, Miligy IM, Gertych A, Jiang Y, Toss MS, Rida P, Ellis IO, Green A, Krishnamurti U, Rakha EA, Aneja R.

Breast Cancer Res. 2019 Jul 29;21(1):83. doi: 10.1186/s13058-019-1165-5.

7.

Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study.

Bhattarai S, Klimov S, Mittal K, Krishnamurti U, Li XB, Oprea-Ilies G, Wetherilt CS, Riaz A, Aleskandarany MA, Green AR, Ellis IO, Cantuaria G, Gupta M, Manne U, Agboola J, Baskovich B, Janssen EAM, Callagy G, Walsh EM, Mehta A, Dogra A, Shet T, Gajaria P, Traina T, Nggada HA, Omonisi A, Ahmed SA, Rakha EA, Rida P, Aneja R.

Cancers (Basel). 2019 Jul 17;11(7). pii: E995. doi: 10.3390/cancers11070995.

8.

Surgical management of ductal carcinoma in situ of the breast: A large retrospective study from a single institution.

Miligy IM, Toss MS, Khout H, Whisker L, Burrell HC, Ellis IO, Green AR, Macmillan D, Rakha EA.

Breast J. 2019 Nov;25(6):1143-1153. doi: 10.1111/tbj.13425. Epub 2019 Jul 18.

PMID:
31318120
9.

Combining clustering and classification ensembles: A novel pipeline to identify breast cancer profiles.

Agrawal U, Soria D, Wagner C, Garibaldi J, Ellis IO, Bartlett JMS, Cameron D, Rakha EA, Green AR.

Artif Intell Med. 2019 Jun;97:27-37. doi: 10.1016/j.artmed.2019.05.002. Epub 2019 May 15.

PMID:
31202397
10.

Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ.

Toss MS, Miligy IM, Gorringe KL, Aleskandarany MA, Alkawaz A, Mittal K, Aneja R, Ellis IO, Green AR, Rakha EA.

Mod Pathol. 2019 Oct;32(10):1460-1472. doi: 10.1038/s41379-019-0286-9. Epub 2019 Jun 7.

PMID:
31175327
11.

Geometric characteristics of collagen have independent prognostic significance in breast ductal carcinoma in situ: an image analysis study.

Toss MS, Miligy IM, Gorringe KL, AlKawaz A, Mittal K, Aneja R, Ellis IO, Green AR, Roxanis I, Rakha EA.

Mod Pathol. 2019 Oct;32(10):1473-1485. doi: 10.1038/s41379-019-0296-7. Epub 2019 Jun 7.

PMID:
31175326
12.

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL): an overview of presentation and pathogenesis and guidelines for pathological diagnosis and management.

Jones JL, Hanby AM, Wells C, Calaminici M, Johnson L, Turton P, Deb R, Provenzano E, Shaaban A, Ellis IO, Pinder SE; National Co-ordinating Committee of Breast Pathology.

Histopathology. 2019 Jun 5. doi: 10.1111/his.13932. [Epub ahead of print]

PMID:
31166611
13.

A key genomic subtype associated with lymphovascular invasion in invasive breast cancer.

Kurozumi S, Joseph C, Sonbul S, Alsaeed S, Kariri Y, Aljohani A, Raafat S, Alsaleem M, Ogden A, Johnston SJ, Aleskandarany MA, Fujii T, Shirabe K, Caldas C, Ashankyty I, Dalton L, Ellis IO, Desmedt C, Green AR, Mongan NP, Rakha EA.

Br J Cancer. 2019 Jun;120(12):1129-1136. doi: 10.1038/s41416-019-0486-6. Epub 2019 May 22.

PMID:
31114020
14.

The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution.

Miligy IM, Toss MS, Gorringe KL, Lee AHS, Ellis IO, Green AR, Rakha EA.

Br J Cancer. 2019 May;120(11):1075-1082. doi: 10.1038/s41416-019-0436-3. Epub 2019 May 8.

PMID:
31065110
15.

Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer.

Kurozumi S, Joseph C, Raafat S, Sonbul S, Kariri Y, Alsaeed S, Pigera M, Alsaleem M, Nolan CC, Johnston SJ, Aleskandarany MA, Ogden A, Fujii T, Shirabe K, Martin SG, Alshankyty I, Mongan NP, Ellis IO, Green AR, Rakha EA.

Breast Cancer Res Treat. 2019 Jul;176(1):63-73. doi: 10.1007/s10549-019-05216-w. Epub 2019 Apr 2.

PMID:
30941650
16.

Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.

Rueda OM, Sammut SJ, Seoane JA, Chin SF, Caswell-Jin JL, Callari M, Batra R, Pereira B, Bruna A, Ali HR, Provenzano E, Liu B, Parisien M, Gillett C, McKinney S, Green AR, Murphy L, Purushotham A, Ellis IO, Pharoah PD, Rueda C, Aparicio S, Caldas C, Curtis C.

Nature. 2019 Mar;567(7748):399-404. doi: 10.1038/s41586-019-1007-8. Epub 2019 Mar 13.

17.

SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment.

Abdel-Fatah TMA, Broom RJ, Lu J, Moseley PM, Huang B, Li L, Liu S, Chen L, Ma RZ, Cao W, Wang X, Li Y, Perry JK, Aleskandarany M, Nolan CC, Rakha EA, Lobie PE, Chan SYT, Ellis IO, Hwang LA, Lane DP, Green AR, Liu DX.

Br J Cancer. 2019 Apr;120(7):728-745. doi: 10.1038/s41416-019-0405-x. Epub 2019 Feb 28.

PMID:
30816325
18.

The molecular mechanisms underlying reduced E-cadherin expression in invasive ductal carcinoma of the breast: high throughput analysis of large cohorts.

Alsaleem M, Toss MS, Joseph C, Aleskandarany M, Kurozumi S, Alshankyty I, Ogden A, Rida PCG, Ellis IO, Aneja R, Green AR, Mongan NP, Rakha EA.

Mod Pathol. 2019 Jul;32(7):967-976. doi: 10.1038/s41379-019-0209-9. Epub 2019 Feb 13.

PMID:
30760857
19.

Behaviour and characteristics of low-grade ductal carcinoma in situ of the breast: literature review and single-centre retrospective series.

Koh VCY, Lim JCT, Thike AA, Cheok PY, Thu MMM, Li H, Tan VKM, Ong KW, Tan BKT, Ho GH, Thilagaratnam S, Wong JSL, Wong FY, Ellis IO, Tan PH.

Histopathology. 2019 Jun;74(7):970-987. doi: 10.1111/his.13837. Epub 2019 Mar 28. Review.

PMID:
30734334
20.

The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ.

Toss MS, Miligy IM, Haj-Ahmad R, Gorringe KL, AlKawaz A, Mittal K, Ellis IO, Green AR, Rakha EA.

Histopathology. 2019 Jun;74(7):1025-1035. doi: 10.1111/his.13835. Epub 2019 Apr 14.

PMID:
30725481
21.

Liver Kinase B1-A Potential Therapeutic Target in Hormone-Sensitive Breast Cancer in Older Women.

Syed BM, Green AR, Morgan DAL, Ellis IO, Cheung KL.

Cancers (Basel). 2019 Jan 28;11(2). pii: E149. doi: 10.3390/cancers11020149.

22.

Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas.

Pareja F, Geyer FC, Brown DN, Sebastião APM, Gularte-Mérida R, Li A, Edelweiss M, Da Cruz Paula A, Selenica P, Wen HY, Jungbluth AA, Varga Z, Palazzo J, Rubin BP, Ellis IO, Brogi E, Rakha EA, Weigelt B, Reis-Filho JS.

NPJ Breast Cancer. 2019 Jan 18;5:6. doi: 10.1038/s41523-018-0101-7. eCollection 2019.

23.

The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer.

El-Ansari R, Craze ML, Alfarsi L, Soria D, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res Treat. 2019 May;175(1):27-38. doi: 10.1007/s10549-018-05111-w. Epub 2019 Jan 22.

PMID:
30671766
24.

Expression of Lamin A/C in early-stage breast cancer and its prognostic value.

Alhudiri IM, Nolan CC, Ellis IO, Elzagheid A, Rakha EA, Green AR, Chapman CJ.

Breast Cancer Res Treat. 2019 Apr;174(3):661-668. doi: 10.1007/s10549-018-05092-w. Epub 2019 Jan 4.

PMID:
30610489
25.

Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.

Joseph C, Arshad M, Kurozomi S, Althobiti M, Miligy IM, Al-Izzi S, Toss MS, Goh FQ, Johnston SJ, Martin SG, Ellis IO, Mongan NP, Green AR, Rakha EA.

Breast Cancer Res Treat. 2019 Apr;174(2):387-399. doi: 10.1007/s10549-018-05085-9. Epub 2018 Dec 15.

PMID:
30554343
26.

Connexin 43 is an independent predictor of patient outcome in breast cancer patients.

Chasampalioti M, Green AR, Ellis IO, Rakha EA, Jackson AM, Spendlove I, Ramage JM.

Breast Cancer Res Treat. 2019 Feb;174(1):93-102. doi: 10.1007/s10549-018-5063-9. Epub 2018 Nov 24.

27.

Glutamate dehydrogenase (GLUD1) expression in breast cancer.

Craze ML, El-Ansari R, Aleskandarany MA, Cheng KW, Alfarsi L, Masisi B, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res Treat. 2019 Feb;174(1):79-91. doi: 10.1007/s10549-018-5060-z. Epub 2018 Nov 23.

PMID:
30470977
28.

Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ.

Toss MS, Miligy IM, Gorringe KL, McCaffrey L, AlKawaz A, Abidi A, Ellis IO, Green AR, Rakha EA.

Mod Pathol. 2019 May;32(5):639-649. doi: 10.1038/s41379-018-0180-x. Epub 2018 Nov 14.

PMID:
30429518
29.

Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS).

Toss MS, Miligy IM, Gorringe KL, AlKawaz A, Khout H, Ellis IO, Green AR, Rakha EA.

Br J Cancer. 2018 Dec;119(12):1518-1526. doi: 10.1038/s41416-018-0337-x. Epub 2018 Nov 9.

30.

Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.

Alfarsi LH, Elansari R, Toss MS, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res Treat. 2019 Jan;173(1):93-102. doi: 10.1007/s10549-018-4978-5. Epub 2018 Oct 10.

PMID:
30306428
31.

An End-to-End Deep Learning Histochemical Scoring System for Breast Cancer TMA.

Liu J, Xu B, Zheng C, Gong Y, Garibaldi J, Soria D, Green A, Ellis IO, Zou W, Qiu G.

IEEE Trans Med Imaging. 2019 Feb;38(2):617-628. doi: 10.1109/TMI.2018.2868333. Epub 2018 Sep 3.

PMID:
30183623
32.

Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition.

Chen X, Low KH, Alexander A, Jiang Y, Karakas C, Hess KR, Carey JPW, Bui TN, Vijayaraghavan S, Evans KW, Yi M, Ellis DC, Cheung KL, Ellis IO, Fu S, Meric-Bernstam F, Hunt KK, Keyomarsi K.

Clin Cancer Res. 2018 Dec 15;24(24):6594-6610. doi: 10.1158/1078-0432.CCR-18-1446. Epub 2018 Sep 4.

PMID:
30181387
33.

Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors.

Pareja F, Brandes AH, Basili T, Selenica P, Geyer FC, Fan D, Da Cruz Paula A, Kumar R, Brown DN, Gularte-Mérida R, Alemar B, Bi R, Lim RS, de Bruijn I, Fujisawa S, Gardner R, Feng E, Li A, da Silva EM, Lozada JR, Blecua P, Cohen-Gould L, Jungbluth AA, Rakha EA, Ellis IO, Edelweiss MIA, Palazzo J, Norton L, Hollmann T, Edelweiss M, Rubin BP, Weigelt B, Reis-Filho JS.

Nat Commun. 2018 Aug 30;9(1):3533. doi: 10.1038/s41467-018-05886-y.

34.

Correction to: Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.

Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JMW, Robertson JF, Ellis IO, Nicholson RI.

Breast Cancer Res. 2018 Aug 30;20(1):98. doi: 10.1186/s13058-018-0999-6.

35.

The role of PIP5K1α/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1α inhibitor.

Sarwar M, Syed Khaja AS, Aleskandarany M, Karlsson R, Althobiti M, Ødum N, Mongan NP, Dizeyi N, Johnson H, Green AR, Ellis IO, Rakha EA, Persson JL.

Oncogene. 2019 Jan;38(3):375-389. doi: 10.1038/s41388-018-0438-2. Epub 2018 Aug 13.

36.

Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer.

Kurozumi S, Joseph C, Sonbul S, Aleskandarany MA, Pigera M, Alsaleem M, Alsaeed S, Kariri Y, Nolan CC, Diez-Rodriguez M, Johnston S, Mongan NP, Fujii T, Shirabe K, Martin SG, Ellis IO, Green AR, Rakha EA.

Breast Cancer Res Treat. 2018 Nov;172(1):61-68. doi: 10.1007/s10549-018-4891-y. Epub 2018 Jul 28.

PMID:
30056565
37.

Impact of breast cancer grade discordance on prediction of outcome.

Rakha EA, Aleskandarany MA, Toss MS, Mongan NP, ElSayed ME, Green AR, Ellis IO, Dalton LW.

Histopathology. 2018 Dec;73(6):904-915. doi: 10.1111/his.13709. Epub 2018 Sep 19.

PMID:
29999192
38.

Intra-operative spectroscopic assessment of surgical margins during breast conserving surgery.

Shipp DW, Rakha EA, Koloydenko AA, Macmillan RD, Ellis IO, Notingher I.

Breast Cancer Res. 2018 Jul 9;20(1):69. doi: 10.1186/s13058-018-1002-2.

39.

Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion.

Sonbul SN, Aleskandarany MA, Kurozumi S, Joseph C, Toss MS, Diez-Rodriguez M, Nolan CC, Mukherjee A, Martin S, Caldas C, Ellis IO, Green AR, Rakha EA.

Mod Pathol. 2018 Nov;31(11):1675-1682. doi: 10.1038/s41379-018-0092-9. Epub 2018 Jun 28.

40.

Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ.

Miligy IM, Gorringe KL, Toss MS, Al-Kawaz AA, Simpson P, Diez-Rodriguez M, Nolan CC, Ellis IO, Green AR, Rakha EA.

Mod Pathol. 2018 Dec;31(12):1807-1815. doi: 10.1038/s41379-018-0086-7. Epub 2018 Jun 28.

PMID:
29955142
41.

Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance.

Althobiti M, Aleskandarany MA, Joseph C, Toss M, Mongan N, Diez-Rodriguez M, Nolan CC, Ashankyty I, Ellis IO, Green AR, Rakha EA.

Histopathology. 2018 Dec;73(6):887-896. doi: 10.1111/his.13695. Epub 2018 Oct 9.

PMID:
29947077
42.

Low expression of G protein-coupled oestrogen receptor 1 (GPER) is associated with adverse survival of breast cancer patients.

Martin SG, Lebot MN, Sukkarn B, Ball G, Green AR, Rakha EA, Ellis IO, Storr SJ.

Oncotarget. 2018 May 25;9(40):25946-25956. doi: 10.18632/oncotarget.25408. eCollection 2018 May 25.

43.

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M.

J Clin Oncol. 2018 Jul 10;36(20):2105-2122. doi: 10.1200/JCO.2018.77.8738. Epub 2018 May 30.

PMID:
29846122
44.

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M.

Arch Pathol Lab Med. 2018 Nov;142(11):1364-1382. doi: 10.5858/arpa.2018-0902-SA. Epub 2018 May 30.

PMID:
29846104
45.

Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas.

Geyer FC, Li A, Papanastasiou AD, Smith A, Selenica P, Burke KA, Edelweiss M, Wen HC, Piscuoglio S, Schultheis AM, Martelotto LG, Pareja F, Kumar R, Brandes A, Fan D, Basili T, Da Cruz Paula A, Lozada JR, Blecua P, Muenst S, Jungbluth AA, Foschini MP, Wen HY, Brogi E, Palazzo J, Rubin BP, Ng CKY, Norton L, Varga Z, Ellis IO, Rakha EA, Chandarlapaty S, Weigelt B, Reis-Filho JS.

Nat Commun. 2018 May 8;9(1):1816. doi: 10.1038/s41467-018-04128-5.

46.

Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis.

Kurozumi S, Joseph C, Sonbul S, Gorringe KL, Pigera M, Aleskandarany MA, Diez-Rodriguez M, Nolan CC, Fujii T, Shirabe K, Kuwano H, Storr S, Martin SG, Ellis IO, Green AR, Rakha EA.

Breast Cancer Res Treat. 2018 Aug;170(3):525-533. doi: 10.1007/s10549-018-4777-z. Epub 2018 Apr 9.

PMID:
29633055
47.

Diagnostic concordance of reporting lymphovascular invasion in breast cancer.

Rakha EA, Abbas A, Pinto Ahumada P, ElSayed ME, Colman D, Pinder SE, Ellis IO.

J Clin Pathol. 2018 Sep;71(9):802-805. doi: 10.1136/jclinpath-2017-204981. Epub 2018 Mar 29.

PMID:
29599396
48.

Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.

Joseph C, Macnamara O, Craze M, Russell R, Provenzano E, Nolan CC, Diez-Rodriguez M, Sonbul SN, Aleskandarany MA, Green AR, Rakha EA, Ellis IO, Mukherjee A.

Br J Cancer. 2018 Apr;118(8):1142-1151. doi: 10.1038/s41416-018-0041-x. Epub 2018 Mar 28.

49.

The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.

El Ansari R, Craze ML, Miligy I, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res. 2018 Mar 22;20(1):21. doi: 10.1186/s13058-018-0946-6.

50.

Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast.

Toss MS, Miligy I, Al-Kawaz A, Alsleem M, Khout H, Rida PC, Aneja R, Green AR, Ellis IO, Rakha EA.

Mod Pathol. 2018 Aug;31(8):1226-1236. doi: 10.1038/s41379-018-0040-8. Epub 2018 Mar 20.

Supplemental Content

Loading ...
Support Center